MedTrace Logo

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

NCT02669511 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-07-09

No results posted yet for this study

Summary

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Conditions

Interventions

DRUG

PQR309

Oral PQR309, 80mg or 60mg daily or intermittent dosing

Sponsors & Collaborators

  • PIQUR Therapeutics AG

    lead INDUSTRY

Principal Investigators

  • Agnieszka Korfel, MD · Charite Universitaetsmedizin Berlin, Germany

  • Uwe Schlegel, Prof · Neurologische UniversitätsklinikKnappschaftskrankenhaus Bochum GmbH

  • Elisabeth Schorb, MD · UNIVERSITÄTSKLINIKUM FREIBURGKlinik für Innere Medizin I

  • Martin Dreyling, Prof · Medizinische Klinik und Poliklinik III Klinikum der Universität München

  • Gerald Illerhaus, Prof · Klinik für Hämatologie, Onkologie und PalliativmedizinStuttgart Cancer

  • Michael Weller, Prof · University of Zurich

  • Daniela Bota, MD · Center101 The City Drive SouthOrange, CA 92686

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-12
Primary Completion
2018-01-12
Completion
2018-01-12
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02669511 on ClinicalTrials.gov